#United States #Minneapolis #Intima Bioscience #Emil Lou #CISH

Dr. Emil Lou and Emma Weston-Dimery Recognized in 2026 TIME100 Health

In a remarkable recognition of their contributions to advancing cancer treatment, Dr. Emil Lou, a distinguished physician and researcher at Intima Bioscience, and his patient Emma Weston-Dimery, have been honored in the 2026 TIME100 Health list. This prestigious list highlights the 100 most influential individuals impacting global health this year, underscoring significant advancements and breakthroughs in the field of oncology.

Intima Bioscience's Commitment to Cancer Treatment

Intima Bioscience is a clinical-stage oncology firm dedicated to innovative approaches targeting solid tumors with the aim of curative intent. Dr. Lou serves as the Principal Investigator for the company's pioneering clinical trial focusing on a novel immune checkpoint known as CISH. His work signifies a potential new avenue in cancer treatment, particularly for patients whose cancers have not responded to conventional therapies.

Emma Weston-Dimery's inclusion in this noteworthy list adds a personal narrative to the medical technology being developed. Having faced a daunting journey battling metastatic Stage 4 colorectal cancer since the age of 23, Weston-Dimery's story is one of resilience and hope. After participating in Dr. Lou's clinical trial, she now stands cancer-free—a testament to Intima's commitment towards potentially life-saving treatments.

The Significance of CISH in Cancer Treatment

The immune checkpoint CISH (cytokine-inducible SH2-containing protein) operates within the intracellular environment, negatively modulating T-cell receptor signaling. This underlines its role in the immune system's ability to recognize cancer cells. By inhibiting CISH in T cells, researchers believe it's possible to counteract immune resistance present in various types of tumors, regardless of PD-L1 expression. Such a mechanism could reshape how cancer is approached, embodying a revolutionary step in immunotherapy.

During the 2025 American Association for Cancer Research Annual Meeting, crucial data regarding Intima's first-in-human studies were presented. This innovative exploration involved utilizing CRISPR technology to knock out the CISH checkpoint in T cells, which were then administered to patients with advanced colorectal cancer. Among the 12 participants, Weston-Dimery emerged as a pivotal case study; her complete clinical response showcases the potential of this groundbreaking research.

The future appears promising as Intima Bioscience is advancing plans to develop an oral small molecule drug aimed at enhancing access to CISH-targeted therapies. This endeavor embodies the hope of democratizing access to cutting-edge cancer treatments, ensuring that a wide array of patients can benefit from these advancements.

Reflections on Recognition

In expressing his gratitude upon receiving this recognition, Dr. Lou stated, "It is an honor to be recognized as part of this year's TIME100 Health. Together with Intima Bioscience, we aim to provide innovative immunotherapy options for patients. The rise in colorectal cancer rates globally, especially among young adults, urges us to push the boundaries of existing treatments."

Weston-Dimery expressed her own heartfelt appreciation, highlighting the support from the Intima team and acknowledging the vital role they played in her recovery journey. "Today, I'm cancer-free, and I'm thankful for everyone who supported us throughout our trials. Being recognized by TIME100 Health is an honor I share with all of those fighting similar battles."

Conclusion

Together, Dr. Emil Lou and Emma Weston-Dimery exemplify the promising intersection of medical innovation and patient experience. Their shared achievement, celebrated in the 2026 TIME100 Health list, offers hope not only to those battling cancer but also serves as an inspiration to the broader medical community. As Intima Bioscience continues its pioneering work in harnessing the power of immunotherapy, the future looks brighter for cancer treatment and care.